An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
eMEET (Medicine Evaluation Educational Training) is designed to help patient advocates “navigate the complex world of medicines development, evaluation and assessment.”
It uses video presentations, animations and exercises to show how patients’ experiences are integrated into scientifically based HTA decisions, with training program modules focused on ‘the journey of a medicine’, ‘an introduction to HTA’, ‘HTA in practice’ and ‘patient advocacy group participation in HTA’.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
February 24th 2025The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
Boehringer Ingelheim Launches Trivalent Vaccine for H5 Avian Influenza
February 24th 2025Launching this month, Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well as for the prevention of Marek disease and infectious bursal disease.